4.5 Review

Automated insulin delivery systems: from early research to routine care of type 1 diabetes

期刊

ACTA DIABETOLOGICA
卷 60, 期 2, 页码 151-161

出版社

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s00592-022-01929-5

关键词

Automated insulin delivery; Closed-loop; Algorithm; Insulin pump; Continuous glucose monitoring

向作者/读者索取更多资源

Automated insulin delivery systems, known as closed-loop systems or artificial pancreas, use blood glucose levels to drive insulin supply, resulting in improved blood sugar control and reduced risk of hypoglycemia for type 1 diabetes patients. Although current AID systems require meal and exercise announcements for insulin adjustment, they represent a significant milestone in diabetes treatment and pave the way for future fully automated and more physiological closed-loop systems.
Automated insulin delivery (AID) systems, so-called closed-loop systems or artificial pancreas, are based upon the concept of insulin supply driven by blood glucose levels and their variations according to body glucose needs, glucose intakes and insulin action. They include a continuous glucose monitoring device which provides a signal to a control algorithm tuning insulin delivery from an infusion pump. The control algorithm is the key of the system since it commands insulin administration in order to maintain blood glucose in a predefined target range and close to a near-normal glucose level. The last two decades have shown dramatic advances toward the use in free life of AID systems for routine care of type 1 diabetes through step-by-step demonstrations of feasibility, safety and efficacy in successive hospital, transitional and outpatient trials. Because of the constraints of pharmacokinetics and dynamics of subcutaneous insulin delivery, the currently available AID systems are all 'hybrid' or 'semi-automated' insulin delivery systems with a need of meal and exercise announcements in order to anticipate rapid glucose variations through pre-meal bolus or pre-exercise reduction of infusion rate. Nevertheless, these AID systems significantly improve time spent in a near-normal range with a reduction of the risk of hypoglycemia and the mental load of managing diabetes in everyday life, representing a milestone in insulin therapy. Expected progression toward fully automated, further miniaturized and integrated, possibly implantable on long-term and more physiological closed-loop systems paves the way for a functional cure of type 1 diabetes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据